<DOC>
	<DOCNO>NCT01137123</DOCNO>
	<brief_summary>The purpose study 1 . To compare effect two type thoracic esophageal cancer lymphadenectomy stag prognosis resectable esophageal cancer , define International Association esophageal disease ( ISDE ) - standard mediastinal lymphadenectomy , total mediastinal lymphadenectomy three field lymphadenectomy , find reasonable range lymphadenectomy . 2 . To compare effect Chemotherapy Group ( Docetaxel + Nedaplatin ) Control Group prognosis resectable thoracic esophageal cancer , explore indication adjuvant chemotherapy .</brief_summary>
	<brief_title>Improve Treatment Thoracic Esophageal Cancer</brief_title>
	<detailed_description>According different location primary lesion，the subject allocate two sub-groups : The patient upper middle thoracic esophageal cancer may assign two field ( T ) -total mediastinal lymphadenectomy group , control group study three field lymphadenectomy-Abdominal + mediastinal + cervical lymphadenectomy group , study group study randomly . After operation , patient whose primary lesion completely ( R0 ) resect assigned adjuvant chemotherapy group interview group randomly .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Age≤70 year old ; 2 . Karnofsky Performance Status（KPS）≥80 ; 3 . Pathological diagnosis squamous cell carcinoma thoracic esophageal treat initially ; 4 . Clinical stage c T 1 ~ 3 N 0 ~ 1 accord result endoscopic ultrasonography，chest abdomen CT neck ultrasonic . 5 . The preoperative evaluation organ function tolerant surgery chemotherapy ; 6 . The subject understand sign inform consent form ( ICF ) ; 7 . The following laboratory test , make 4 week first medication , confirm bone marrow , liver kidney function line requirement participate research ; Hemoglobin（HGB）≥9.0g/L ; absolute neutrophils count（ANC）≥1.5×109/L ; platelet count（PLT）≥100×109/L ; total bilirubin（TBIL）≤1.5N ; aspartate aminotransferase ( AST ) ≤2.5N ; alanine aminotransferase ( ALT ) ≤2.5N ; prothrombin time ( PT ) ≤1.5N , activate partial thromboplastin time ( APTT ) normal range ; endogenous creatinine clearance rate ( CRE ) ≤1.5N . 1 . Cervical esophageal cancer Nonsquamous cell carcinoma thoracic esophageal cancer ; 2 . Advanced Esophageal Cancer ; 3 . Prior malignancy 5 year recently ; 4 . History previous chest radiotherapy ; 5 . History cardiocerebral vascular accident 6 month lately ; 6 . The subject understand sign inform consent form ( ICF ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>esophageal squamous cell carcinoma</keyword>
</DOC>